Renal replacement therapy efficiently eliminates cefepime. A published in vitro study concluded to minimal adsorption of cefepime in a polysulfone derived filter. We aimed at assessing cefepime adsorption in filters used in critically ill patients.
Methods:
Two filters were used, ST™150 and AV™1000. Adsorption was assessed in two modes, including diafiltration and filtration set to flow rates of from 2.5 to 1 L/h, respectively. Routes of elimination were assessed using NeckEpur® method for 6-h session duration.
Results:
The mean initial concentration in the 5-L central compartment (CC) in the 10 sessions was 47.7 ± 2.9 mg/L. Using the diafiltration mode, the mean adsorption rates in the ST™150 and AV™1000 were 1.3 ± 2.3% and 19.7 ± 1.2% (n = 3), respectively. Using the filtration mode at 1 L/h, the mean adsorption rates in the ST™150 and AV™1000 were 1.7% (n = 2) and 18.5% (n = 2), respectively.
Conclusion:
ST™150 filter sequestrated very limited quantities of cefepime. In the diafiltration and filtration modes, AV™1000 sequestered cefepime at about 19%. The adsorption rate seems independent of the flow rate. Further studies would be needed to assess, in particular, the clinical relevance of these results in adults as well as drug adsorption in the pediatric population.
BarradellLBBrysonHM.Cefepime: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs1994; 47: 471–505.
2.
IslerBHarrisPStewartAG, et al. An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa. J Antimicrob Chemother2021; 76: 550–560.
3.
AlshaerMHGoutelleSSantevecchiBA, et al. Cefepime precision dosing tool: from standard to precise dose using nonparametric population pharmacokinetics. Antimicrob Agents Chemother2022; 66: e02046-21.
4.
ImburgiaTAEngdahlSRPettitRS. Evaluation of the safety of cefepime prolonged infusions in pediatric patients with cystic fibrosis. Pediatr Pulmonol. 2022;57(4):919–25.
5.
LeCleirLKPettitRS.Piperacillin-tazobactam versus cefepime incidence of acute kidney injury in combination with vancomycin and tobramycin in pediatric cystic fibrosis patients. Pediatr Pulmonol2017; 52: 1000–1005.
6.
BarbhaiyaRHKnuppCAForgueST, et al. Pharmacokinetics of cefepime in subjects with renal insufficiency. Clin Pharmacol Ther1990; 48: 268–276.
7.
ChapuisTMGiannoniEMajcherczykPA, et al. Rperseoarschpective monitoring of cefepime in intensive care unit adult patients. Crit Care2010; 14(2): R51.
8.
HuwylerTLenggenhagerLAbbasM, et al. Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study. Clin Microbiol Infect2017; 23: 454–459.
9.
KieftHHoepelmanAIMKnuppCA, et al. Pharmacokinetics of cefepime in patients with the sepsis syndrome. J Antimicrob Chemother1993; 32 suppl B: 117–122.
10.
IslaAGascónARMaynarJ, et al. Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients. Clin Ther2005; 27: 599–608.
11.
CarlierMTacconeFSBeumierM, et al. Population pharmacokinetics and dosing simulations of cefepime in septic shock patients receiving continuous renal replacement therapy. Int J Antimicrob Agents2015; 46: 413–419.
12.
PhilpottCDDroegeCADroegeME, et al. Pharmacokinetics and pharmacodynamics of extended-infusion cefepime in critically ill patients receiving continuous renal replacement therapy: a prospective, open-label study. Pharmacotherapy2019; 39: 1066–1076.
13.
ChaijamornWCharoensareeratTSrisawatN, et al. Cefepime dosing regimens in critically ill patients receiving continuous renal replacement therapy: a Monte Carlo simulation study. J Intensive Care2018; 6: 61.
14.
GreenDJWattKMFishDN, et al. Cefepime extraction by extracorporeal life support circuits. J Extracorpor Technol2022; 54: 212–222.
15.
BaudFJHouzéPCarliP, et al. Alteration of the pharmacokinetics of aminoglycosides by adsorption in a filter during continuous renal replacement therapy. An in vitro assessment. Therapies2021; 76: 415–424.
16.
BaudFJHouzéPRaphalenJ-HWinchenneA, et al. Diafiltration flowrate is a determinant of the extent of adsorption of amikacin in renal replacement therapy using the ST150®-AN69 filter: an in vitro study. Int J Artif Organs2020; 43: 758–766.
17.
BaudFJSeifVHouzéP, et al. Elimination of three doses of gentamicin over three consecutive days using a polyacrylonitrile-derived filter: an in vitro assessment. Int J Artif Organs2021; 44: 641–650.
18.
BaudFJJullienVAbarouT, et al. Elimination of fluconazole during continuous renal replacement therapy. An in vitro assessment. Int J Artif Organs2021; 44: 453–464.
19.
Le VenJPellanCMauletV, et al. Elimination of cefotaxime using polysulfone and polyacrylonitrile-derived filters: an in vitro assessment. Int J Artif Organs2023; 46: 113–119.
20.
BaudFJ.Elimination of voriconazole during continuous renal replacement therapy. An in vitro assessment. (SFAR) Société française d’anesthésie et de réanimation. 2021 sept; Paris. France.
21.
KronfolNOLauAHBarakatMM.Aminoglycoside binding to polyacrylonitrile hemofilter membranes during continuous hemofiltration. ASAIO Trans1987; 33: 300–303.
22.
BranickKTaylorMJTrumpMW, et al. Apparent interference with extracorporeal membrane oxygenation by liposomal amphotericin B in a patient with disseminated blastomycosis receiving continuous renal replacement therapy. Am J Health Syst Pharm2019; 76: 810–813.
23.
MathieuAThiboutotZFerreiraV, et al. Voriconazole sequestration during extracorporeal membrane oxygenation for invasive lung aspergillosis: a case report. ASAIO J2021; 68(3): e56–e58.
24.
RaphalenJHMarcaisAParizeP, et al. Is caspofungin efficient to treat invasive candidiasis requiring continuous veno-venous hemofiltration? A case report. Therapie2020; 76(5): 512–515.
RowlandMTozerTN.Elimination. In: RowlandMTozerTN (eds) Clinical Pharmacokinetics. Concepts and Applications. 3rd ed.Baltimore: Williams & Wilkins, 1995, pp.156–183.
27.
RowlandMTozerTN.Clinical pharmacokinetics. Concepts and applications. 3rd ed.Baltimore: Williams & Wilkins, 1995.
28.
YuSLiSYangH, et al. A novel liquid chromatography/tandem mass spectrometry based depletion method for measuring red blood cell partitioning of pharmaceutical compounds in drug discovery. Rapid Commun Mass Spectrom2005; 19: 250–254.
SimeFBLassig-SmithMStarrT, et al. A population pharmacokinetic model-guided evaluation of ceftolozane-tazobactam dosing in critically ill patients undergoing continuous venovenous hemodiafiltration. Antimicrob Agents Chemother2019; 64: e01655-19.
31.
PfallerMADiekemaDJOstrosky-ZeichnerL, et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol2008; 46: 2620–2629.
32.
MaloneRSFishDNAbrahamE, et al. Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother2001; 45: 3148–3155.
33.
SeylerLCottonFTacconeFS, et al. Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit Care2011; 15: R137.
34.
Al-ShaerMHMaguiganKAshtonJ, et al. Applying cefepime population pharmacokinetics to critically ill patients receiving continuous renal replacement therapy. Antimicrob Agents Chemother2022; 66: e0161121.
35.
StittGMorrisJSchmeesL, et al. Cefepime pharmacokinetics in critically ill pediatric patients receiving continuous renal replacement therapy. Antimicrob Agents Chemother2019; 63: e02006-18.
36.
PhillipsGJDaviesJGOlliffCJ, et al. Use of in vitro models of haemofiltration and haemodiafiltration to estimate dosage regimens for critically ill patients prescribed cefpirome. J Clin Pharm Ther1998; 23: 353–359.
37.
BaudFJHouzéP.Should in vitro and in vivo studies on antimicrobial agents during continuous renal replacement therapy comply with general principles of pharmacokinetics?Antimicrob Agents Chemother2020; 64: e00388-20.
38.
BaudFJJullienVSecretanPH, et al. Are we correctly treating invasive candidiasis under continuous renal replacement therapy with echinocandins? Preliminary in vitro assessment. Anaesth Crit Care Pain Med2020; 40:100640.
39.
HouzéPBaudFJRaphalenJ-H, et al. Continuous renal replacement therapy in the treatment of severe hyperkalemia: an in vitro study. Int J Artif Organs2020; 43: 87–93.
